Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...
The first ApDC to have FDA orphan drug designation globally, the drug was jointly developed by researchers from HIM and Wenzhou Medical University. Orphan drugs are drugs specifically used to treat ...